PODD Insulet Corporation

Ayrshire Capital Management LLC has reduced its stake in Insulet Corporation (NASDAQ:PODD) by 19.6%, selling 4,619 shares and now holding 18,942 shares valued at $5.85 million. Despite this, Insulet accounts for a significant portion of Ayrshire's portfolio, and the company has still received positive ratings from analysts, with a consensus of "Moderate Buy" and an average price target of $379.00. Insulet recently reported strong quarterly EPS of $1.24, surpassing estimates, and a 29.9% year-over-year revenue increase, although it missed revenue estimates.

The Global Disposable Insulin Pumps Market is projected to grow from US$ 3.83 billion in 2024 to US$ 6.9 billion by 2032, exhibiting a CAGR of 7.76%. This growth is driven by recent innovations and increasing adoption of tubeless patch pumps for diabetes management in regions like the US and Europe. Key players in this market include Medtronic, Insulet Corporation, and Roche.

Insulet Corporation (NASDAQ:PODD) has received a consensus "Moderate Buy" rating from 25 analysts, with an average 1-year price target of $379.00. Analysts have been increasing their price targets, and the company recently beat EPS estimates ($1.24 vs. $1.13 est.) while revenue grew 29.9% year-over-year, despite missing consensus. The stock trades near $288 with a market cap of approximately $20.3 billion.

Glaukos Corporation is well-positioned for growth due to the successful launch of its iDose TR product and its robust product pipeline, despite facing stiff competition. The company's shares have significantly outperformed the industry this year, driven by strong adoption of iDose TR and the recent FDA approval of Epioxa, which is set to boost its corneal health franchise. While reimbursement complexities and a temporary revenue disruption during the Epioxa transition pose challenges, Glaukos' diversified global growth, strong financial profile, and ongoing innovation support its positive outlook.

Swedbank AB increased its stake in Insulet Corporation by 6.9% in Q3, purchasing 5,000 shares to own 77,488 shares valued at approximately $23.9 million. Insulet (NASDAQ:PODD) holds a "Moderate Buy" consensus rating from analysts, with various price target adjustments from firms like JPMorgan and Truist. The company recently exceeded EPS expectations but fell short on revenue estimates in its latest earnings report.

Osaic Holdings Inc. significantly increased its stake in Insulet Corporation by 152.9% in Q2, acquiring 5,309 additional shares to hold a total of 8,781 shares valued at approximately $2.709 million. Wall Street analysts maintain a "Moderate Buy" consensus rating for Insulet, with several firms recently raising their price targets. Insulet also reported Q1 EPS of $1.24, beating estimates, and revenue growth of 29.9% year-over-year.